Book > Protein Kinase Inhibitors As Sensitizing Agents For Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Detail Book : Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy written by , published by Academic Press which was released on 21 November 2018. Download Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy Books now! Available in PDF, ePub and Kindle. Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment

GET BOOK
Author :
Release Date : 21 November 2018
Publisher : Academic Press
Rating : 5/5 (from 1 users)
Pages : 292
ISBN : 0128127384
Format : PDF, ePUB, KF8, PDB, MOBI, Tuebl
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have

GET BOOK
Drug Efflux Pumps in Cancer Resistance Pathways  From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy

Drug Efflux Pumps in Cancer Resistance Pathways From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy

Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Volume Seven, describes the fundamental aspects of efflux pumps of the ATP-binding cassette superfamily in cancer resistance pathways, along with strategies to target and improve chemotherapy efficacy. Pumps of the ATP-binding cassette

GET BOOK
pH Interfering Agents as Chemosensitizers in Cancer Therapy

pH Interfering Agents as Chemosensitizers in Cancer Therapy

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results.

GET BOOK
Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This

GET BOOK
Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing,

GET BOOK
Prognostic and Therapeutic Applications of Rkip in Cancer

Prognostic and Therapeutic Applications of Rkip in Cancer

Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expression levels for diagnostics, prognosis and potential interventions. The development of novel compounds and conjugates that selectively induce RKIP expression in cancer open a novel era of

GET BOOK
The Breast E Book

The Breast E Book

The Breast: Comprehensive Management of Benign and Malignant Diseases, 4th Edition, by Kirby I. Bland, MD, and Edward M. Copeland, III, MD, is a surgical reference that offers the most comprehensive, up-to-date resource on the diagnosis and management of, and rehabilitation following, surgery for benign and malignant diseases of the

GET BOOK
Protein Kinase C in Cancer Signaling and Therapy

Protein Kinase C in Cancer Signaling and Therapy

Protein kinase C (PKC), a family of serine-threonine kinases, rocketed to the forefront of the cancer research field in the early 1980’s with its identification as an effector of phorbol esters, natural products with tumor promoting activity. Phorbol esters had long been of interest to the cancer research field due

GET BOOK
Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring

GET BOOK
Chemoradiation in Cancer Therapy

Chemoradiation in Cancer Therapy

Internationally recognized experts in cancer biology and clinical research review the present status of the multimodality approach to the management of solid tumors and speculate on possible future strategies for chemoradiation therapy. The authors detail applications of combined modality therapy in lung, esophageal, breast, gastric, pancreatic, colon, and rectal cancers.

GET BOOK
Advances in DNA Repair

Advances in DNA Repair

This book edition is intended to provide a concise summary for select topics in DNA repair, a field that is ever-expanding in complexity and biologic significance. The topics reviewed ranged from fundamental mechanisms of DNA repair to the interface between DNA repair and a spectrum on cellular process to the

GET BOOK
Oncogene Directed Therapies

Oncogene Directed Therapies

Prominent investigators and clinicians summarize in a balanced blend of fundamental science, basic research, experimental therapeutics, and early clinical experiences, what is known about oncogenes and oncogenesis, and describe how that knowledge can be used to treat the cancer. The contributors explain how, why, and under what conditions certain proteins

GET BOOK
Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

​​​​​This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be

GET BOOK
Checkpoint Controls and Targets in Cancer Therapy

Checkpoint Controls and Targets in Cancer Therapy

Much work over the last two decades has firmly established that loss of cell cycle checkpoint regulation, and resultant unabated cellular proliferation, is an inherent characteristic of cancer. This loss may occur through aberration in any single component involved in signal transduction pathways that orchestrate checkpoint regulation, which may manifest

GET BOOK
Colorectal Cancer

Colorectal Cancer

With international experts sharing their experience and knowledge on these different aspects in the management of colorectal cancer, this book has this opportunity to offer all physicians treating colorectal cancer, as well as researchers, updated information concerning the biology, diagnosis, screening, and treatment of colorectal carcinoma. This book provides a

GET BOOK